{"id":"oral-l-ornithine-aspartate-administration","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL446143","moleculeType":"Small molecule","molecularWeight":"132.16"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"L-ornithine aspartate is a combination of the amino acid L-ornithine and aspartic acid. By increasing ornithine levels, it may help to reduce ammonia levels in the blood, which can be beneficial for patients with hepatic encephalopathy.","oneSentence":"Oral L-ornithine aspartate administration increases ornithine levels in the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:42.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatic encephalopathy"}]},"trialDetails":[{"nctId":"NCT05920213","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2023-10","conditions":"Hepatic Encephalopathy Stage 2, Hepatic Encephalopathy Stage 3, Hepatic Encephalopathy Stage 4","enrollment":360},{"nctId":"NCT03577938","phase":"NA","title":"Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment","status":"COMPLETED","sponsor":"Beijing 302 Hospital","startDate":"2019-01-10","conditions":"Acute on Chronic Liver Failure, Traditional Chinese Medicine, Hepatitis B","enrollment":516},{"nctId":"NCT05042024","phase":"PHASE3","title":"Supplementation With L-ornithine But Not L-arginine Increases Density of CD68+ and CD163+ Macrophages in Periodontitis","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2017-10-20","conditions":"Periodontitis","enrollment":75},{"nctId":"NCT00896831","phase":"PHASE4","title":"Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2008-11","conditions":"Hepatic Encephalopathy","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oral supplementation with Larnamin (Farmak, Ukraine)"],"phase":"phase_3","status":"active","brandName":"Oral L-ornithine aspartate administration","genericName":"Oral L-ornithine aspartate administration","companyName":"Ukrainian Medical Stomatological Academy","companyId":"ukrainian-medical-stomatological-academy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral L-ornithine aspartate administration increases ornithine levels in the body. Used for Hepatic encephalopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}